Adamas Completes Acquisition of OSMOLEX ER®

(January 5, 2021) – Adamas completed acquisition of OSMOLEX ER® via a settlement of patent litigation with Osmotica Pharmeceuticals US LLC. OSMOLEX ER® is an FDA-approved, extended-release tablet for the treatment of Parkinson’s disease. Click here to learn more about Adamas and OSMOLEX ER®.

Follow Us Follow us on TwitterFollow us on FacebookInstagram

Sign Up for Email Alerts

By providing your email you agree to receive periodic emails from The Parkinson Alliance.

Please tell us more about yourself:

This month is? (Anti-Spam)

Contact UsTerms Of UsePrivacy Policy

The Parkinson Alliance is a nonprofit, tax-exempt charitable organization under section 501(c)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law. Copyright © 2020 The Parkinson Alliance. All rights reserved.